A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines (CLEAR)
Latest Information Update: 23 Feb 2026
At a glance
- Drugs Lesigercept (Primary)
- Indications Chronic urticaria
- Focus Therapeutic Use
- Acronyms CLEAR
- Sponsors Yuhan
Most Recent Events
- 23 Feb 2026 New trial record